Physiologic Response to Glucagon at Varying Insulin Levels
The Hepatic Glucose Response to Glucagon at Varying Insulin Levels: Implications for Closed Loop Glycemic Control.
연구 개요
상세 설명
We investigators have been working on the development of a closed loop (artificial endocrine pancreas) insulin and glucagon infusion system since 2005 and are part of the Juvenile Diabetes Research Foundation Artificial Pancreas Consortium. As part of our studies, we give small doses of glucagon to prevent hypoglycemia. As we assessed the success and failure of glucagon administration during these studies, we found the use of glucagon reduced the frequency of hypoglycemia by about 75%. However, the fact that approximately 25% of administrations of glucagon are ineffective remains a concern.
The primary question to be addressed by this study is, in the setting of low dose subcutaneous glucagon administration, how do plasma glucagon and plasma insulin quantitatively interact? In other words, as the rate of insulin administration is increased, how much more glucagon is necessary to overcome the effect of insulin to prevent hypoglycemia? This study is designed to address this question. Subjects will be brought in to a Legacy Hospital for four 10 hour experiments on each of four separate days. On each study day, there will be a continuous infusion of a different rate of IV Regular insulin in order to achieve different steady state free insulin levels. At each insulin level, there will be four subcutaneous glucagon doses given. Octreotide will be infused by IV at a constant rate to suppress endogenous production of glucagon. A stable glucose isotope will also be infused to allow for measurement of hepatic glucose production and glucose turnover. Arterialized venous blood glucose will be measured by the HemoCue Glucose 201 Analyzer.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Legacy Health System
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Diagnosis of type 1 diabetes mellitus for at least 1 year
- Male or female subjects 21 to 65 years of age
- Current use of an insulin pump
- Willingness to sign informed consent and HIPAA documents and follow all study procedures
Exclusion Criteria:
- Pregnancy or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study
- Renal insufficiency (serum creatinine of 2.0 mg/dL or greater)
- Liver abnormalities: Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.3 g/dL; or serum bilirubin of over 2
- Adrenal insufficiency
- Hematocrit of less than or equal to 34%
- A history of cerebrovascular disease or coronary artery disease regardless of the time since occurrence
- Congestive heart failure, NYHA class III or IV
- Cardiac rhythm disturbance characterized by: 2nd or 3rd degree heart block, bradycardia of less than 50 bpm (exception of bradycardia in an aerobic athlete), tachycardia of greater than 100 bpm, or any arrhythmia judged by the investigator to be exclusionary
- Any active infection
- Active foot ulceration
- Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication
- Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator)
- Active malignancy, except basal cell or squamous cell skin cancers
- Major surgical operation within 30 days prior to screening
- Seizure disorder
- Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen
- Chronic usage of any immunosuppressive medication
- Current administration of oral or parenteral corticosteroids
- Use of an investigational drug within 30 days prior to screening
- Bleeding disorder, treatment with warfarin, or platelet count below 50,000
- Allergy to glucagon
- Past history of pheochromocytoma or a family history of MEN 2, neurofibromatosis, or von Hippel-Lindau disease
- Insulin resistance requiring more than 200 units per day
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low, Medium and High insulin infusion
All study subjects in this arm were randomized as follows: First study is regular insulin infused at lowest level with glucagon administration. Second study is regular insulin infused at medium level with glucagon adminstration. Third study is regular insulin infused at highest level with glucagon administration. |
The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started.
The subsequent three doses will be delivered every two hours.
The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175.
Insulin levels and glucagon doses will be randomized.
Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
다른 이름들:
Insulin was administered at a low, medium or high infusion rate.
The intervention sequence was randomly pre-determined for all participants.
다른 이름들:
|
|
실험적: Low, High and Medium insulin infusion
All study subjects in this arm were randomized as follows: First study is regular insulin infused at lowest level with glucagon administration. Second study is regular insulin infused at highest level with glucagon adminstration. Third study is regular insulin infused at medium level with glucagon administration. |
The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started.
The subsequent three doses will be delivered every two hours.
The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175.
Insulin levels and glucagon doses will be randomized.
Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
다른 이름들:
Insulin was administered at a low, medium or high infusion rate.
The intervention sequence was randomly pre-determined for all participants.
다른 이름들:
|
|
실험적: Medium, Low and High insulin infusion
All study subjects in this arm were randomized as follows: First study is regular insulin infused at medium level with glucagon administration. Second study is regular insulin infused at lowest level with glucagon adminstration. Third study is regular insulin infused at highest level with glucagon administration. |
The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started.
The subsequent three doses will be delivered every two hours.
The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175.
Insulin levels and glucagon doses will be randomized.
Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
다른 이름들:
Insulin was administered at a low, medium or high infusion rate.
The intervention sequence was randomly pre-determined for all participants.
다른 이름들:
|
|
실험적: Medium, High and Low insulin infusion
All study subjects in this arm were randomized as follows: First study is regular insulin infused at medium level with glucagon administration. Second study is regular insulin infused at highest level with glucagon adminstration. Third study is regular insulin infused at lowest level with glucagon administration. |
The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started.
The subsequent three doses will be delivered every two hours.
The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175.
Insulin levels and glucagon doses will be randomized.
Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
다른 이름들:
Insulin was administered at a low, medium or high infusion rate.
The intervention sequence was randomly pre-determined for all participants.
다른 이름들:
|
|
실험적: High, Low and Medium insulin infusion
All study subjects in this arm were randomized as follows: First study is regular insulin infused at highest level with glucagon administration. Second study is regular insulin infused at lowest level with glucagon adminstration. Third study is regular insulin infused at medium level with glucagon administration. |
The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started.
The subsequent three doses will be delivered every two hours.
The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175.
Insulin levels and glucagon doses will be randomized.
Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
다른 이름들:
Insulin was administered at a low, medium or high infusion rate.
The intervention sequence was randomly pre-determined for all participants.
다른 이름들:
|
|
실험적: High, Medium and Low insulin infusion
All study subjects in this arm were randomized as follows: First study is regular insulin infused at highest level with glucagon administration. Second study is regular insulin infused at medium level with glucagon adminstration. Third study is regular insulin infused at lowest level with glucagon administration. |
The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started.
The subsequent three doses will be delivered every two hours.
The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175.
Insulin levels and glucagon doses will be randomized.
Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
다른 이름들:
Insulin was administered at a low, medium or high infusion rate.
The intervention sequence was randomly pre-determined for all participants.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area Under the Curve for Glucose Above Baseline
기간: 60 minutes after each glucagon administration
|
The change in the rate of glucose appearance will be assessed by measuring the stable glucose isotope (dideuterated glucose, D2) using a gas chromatography-mass spectrometry assay.
The units of the area under the curve are defined as milligrams per kilogram of glucose, since the dependent variable is a rate of glucose production [mg/kg/min] measured over time [min].
The time variable therefore cancels out.
Additionally, this area under the curve is being normalized per microgram of glucagon delivered.
|
60 minutes after each glucagon administration
|
공동 작업자 및 조사자
수사관
- 수석 연구원: W Kenneth Ward, MD, Legacy Health System
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- kw02
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
Glucagon에 대한 임상 시험
-
Mayo ClinicAstellas Pharma US, Inc.; University of Nebraska; Lantheus Medical Imaging완전한